Scynexis has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Scynexis, 2018, MAR 13, 2018, View Source [SID1234524715]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 13, 2018 Delcath Systems presented Investor Presentation dated March, 2018 (Presentation, Delcath Systems, MAR 13, 2018, View Source [SID1234524730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 13, 2018 GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA) reported that Shawn Cross, Chairman and Chief Executive Officer, and Raymond Urbanski, Chief Medical Officer, will present a company overview at the Roth Capital Partners 30th Annual Conference on Tuesday, March 13, at 11:30 a.m. PT (Press release, GT Biopharma , MAR 13, 2018, View Source [SID1234539532]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event will be available via the ‘Investor Relations’ page of the GT Biopharma website, View Source Please log on through GT Biopharma’s website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Gt Biopharma’s website for 90 days following the call.

On March 13, 2018 Diplomat Pharmacy Inc. (NYSE: DPLO) reported that it will send executives to the 2018 Barclays Global Healthcare Conference in Miami, Florida (Press release, Diplomat Speciality Pharmacy, MAR 13, 2018, View Source [SID1234524731]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

­Interim CEO Jeff Park, President Joel Saban, and Chief Financial Officer Atul Kavthekar are scheduled to present at 2:35 p.m. ET Wednesday, March 14.

On March 13, 2018 Avelas Biosciences, Inc., a clinical stage oncology-focused platform technology company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, reported that Carmine N. Stengone, President and Chief Executive Officer, will present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018, at 4:10 p.m. EDT (1:10 p.m. PDT) in New York City (Press release, Avelas Biosciences, MAR 13, 2018, View Source [SID1234525081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!